Clinical studies have strongly associated circulating asprosin levels with disease severity in conditions such as obesity, MASLD, and other obesity‐related cardiometabolic conditions.[33, 34] By studying MASLD patients and mice, we confirm that plasma asprosin levels are positively correlated with markers of liver injury as well as TC and TG. This evidence concerns the gene FBN1 and metabolic dysfunction-associated steatotic liver disease.